ConductScience.org, home

Paper40533769

Aurora kinases signaling in cancer: from molecular perception to targeted therapies.

Vats P and 6 others. Mol Cancer, 2025. Cited by 29 papers, by iCite.

Cite this record

ConductScience Library. Aurora kinases signaling in cancer: from molecular perception to targeted therapies. Papers, record 40533769. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40533769

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aurora kinases signaling in cancer: from molecular perception to targeted therapies.
PubMed
Journal
Mol Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
29
iCite
Relative citation ratio, by iCite
7.6, provisional
iCite
Revised in PubMed
2026-10-29
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vats PPrerna
2Saini CChainsee
3Baweja BBhavika
4Srivastava SKSandeep K
5Kumar AAshok
6Kushwah ASAtar Singh
7Nema RRajeev

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Aurora KinasesMajor topic
Molecular Targeted TherapyMajor topic
Protein Kinase InhibitorsMajor topic
Signal TransductionMajor topic
Humans
Animals
Antineoplastic Agents

Source PubMed

Download CSV of topics

References360

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119567821GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.Mol Cancer Ther2009https://conductscience.org/library/papers/19567821PubMed
231837959Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.Lancet Haematol2020https://conductscience.org/library/papers/31837959PubMed
320560971Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.Br J Haematol2010https://conductscience.org/library/papers/20560971PubMed
439589337Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas.Clin Cancer Res2025https://conductscience.org/library/papers/39589337PubMed
58293973Isolation and characterization of chromosome-gain and increase-in-ploidy mutants in yeast.Genetics1993https://conductscience.org/library/papers/8293973PubMed
629551775Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.Br J Cancer2018https://conductscience.org/library/papers/29551775PubMed
720001553Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.Expert Opin Investig Drugs2010https://conductscience.org/library/papers/20001553PubMed
815501446Aurora kinases in spindle assembly and chromosome segregation.Exp Cell Res2004https://conductscience.org/library/papers/15501446PubMed
934465813Genetic variations in AURORA cell cycle kinases are associated with glioblastoma multiforme.Sci Rep2021https://conductscience.org/library/papers/34465813PubMed
1034083040Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.Mutat Res Rev Mutat Res2021https://conductscience.org/library/papers/34083040PubMed
1136509911Rational combinations of targeted cancer therapies: background, advances and challenges.Nat Rev Drug Discov2023https://conductscience.org/library/papers/36509911PubMed
1235868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022https://conductscience.org/library/papers/35868306PubMed
1321206969Quercetin inhibits a large panel of kinases implicated in cancer cell biology.Int J Oncol2011https://conductscience.org/library/papers/21206969PubMed
1434866972Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects.Saudi J Biol Sci2021https://conductscience.org/library/papers/34866972PubMed
1519155085The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.J Hepatol2009https://conductscience.org/library/papers/19155085PubMed
1625882311Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression.Mol Cancer Ther2015https://conductscience.org/library/papers/25882311PubMed
1738001709Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study.Cancers (Basel)2023https://conductscience.org/library/papers/38001709PubMed
1837958352Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications.Cancers (Basel)2023https://conductscience.org/library/papers/37958352PubMed
1934967265Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2.Bioengineered2022https://conductscience.org/library/papers/34967265PubMed
2021785464Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death.Oncogene2012https://conductscience.org/library/papers/21785464PubMed

See all 360 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.

PMIDTitleJournalYearIn PapersSource
42821234ASO Author Reflections: Clinical Relevance of Aurora Kinase A (AURKA) Gene Expression in ER+/HER2- Breast Cancer.Ann Surg Oncol2026https://conductscience.org/library/papers/42821234PubMed
42794728Expanding Synthetic Lethality in DNA Damage Response-Defective Cancers Through Stress Phenotype-Guided Kinase Targeting.Int J Mol Sci2026https://conductscience.org/library/papers/42794728PubMed
42789740Aurora kinase a phosphorylates and stabilizes UHRF1 to maintain DNA methylation and prostate cancer cell survival.Epigenetics2026https://conductscience.org/library/papers/42789740PubMed
42773299Pharmacological inhibition of UBASH3B induces mitotic arrest and selectively reduces tumor growth.EMBO Mol Med2026https://conductscience.org/library/papers/42773299PubMed
42760281Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42760281PubMed
42749405Investigating the prognostics and theranostic cell cycle-related genes of Hinokinin in high-grade glioma: an integrated network pharmacology, bioinformatics, and molecular docking approach.J Genet Eng Biotechnol2026https://conductscience.org/library/papers/42749405PubMed
42706431Aurora A exacerbates antibiotic-resistant Staphylococcus aureus infection through ASC phosphorylation.EMBO Rep2026https://conductscience.org/library/papers/42706431PubMed
42671316Cancer cell-selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy.Clin Transl Med2026https://conductscience.org/library/papers/42671316PubMed
42645201A Regulatory Element in the Intrinsically Disordered C-Terminal Region of LMTK3 Modulates Its Kinase Domain Interactions and Breast Cancer Phenotypes.Cells2026https://conductscience.org/library/papers/42645201PubMed
42640371Exceptional treatment responses and molecular markers among 103 colorectal cancer cell lines.Mol Biomed2026https://conductscience.org/library/papers/42640371PubMed
42578512Structure-based screening and identification of a novel Aurora-A-targeting peptide with antiproliferative activity against prostate cancer cells.J Enzyme Inhib Med Chem2026https://conductscience.org/library/papers/42578512PubMed
42531323Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor-Resistant Head and Neck Squamous Cell Carcinoma.Cancer Res Commun2026https://conductscience.org/library/papers/42531323PubMed
42490878Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives.Front Oncol2026https://conductscience.org/library/papers/42490878PubMed
42445377LINC01614 favors breast cancer progression through the regulation of miR-217/FN1 and mediation in PI3K/AKT signal pathway.Transl Cancer Res2026https://conductscience.org/library/papers/42445377PubMed
42380670AURORA A interacts with DICER and SETD2 to promote S-phase progression.EMBO Rep2026https://conductscience.org/library/papers/42380670PubMed
42307783Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer.Funct Integr Genomics2026https://conductscience.org/library/papers/42307783PubMed
42199350TPX2 as a prognostic biomarker and potential therapeutic target for malignant melanoma proliferation and metastasis.Exp Ther Med2026https://conductscience.org/library/papers/42199350PubMed
42092929Interferon lambda in anti-viral defense and cancer: dual roles, mechanism and therapeutic potential.J Transl Med2026https://conductscience.org/library/papers/42092929PubMed
42042038Dysregulation of Aurora Kinases and AURKAIP1 Promoter Methylation as Potential Peripheral Diagnostic Biomarkers in Acute Myeloid Leukemia.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42042038PubMed
42028206Discovery of thieno[2,3-d]pyrimidine-based dual Aurora B/VEGFR-2 inhibitors with potent anticancer activity: molecular docking, mechanistic studies, and in vivo validation in a breast cancer model.RSC Adv2026https://conductscience.org/library/papers/42028206PubMed

See all 28 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AURKA6790PubTator's text mininghttps://conductscience.org/library/genes/6790NCBI Gene
AURKB9212PubTator's text mininghttps://conductscience.org/library/genes/9212NCBI Gene
AURKC6795PubTator's text mininghttps://conductscience.org/library/genes/6795NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40533769

GET https://conductscience.org/api/papers/v1/40533769/references?page=2